{"id":"NCT04296890","sponsor":"ImmunoGen, Inc.","briefTitle":"A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression","officialTitle":"SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-23","primaryCompletion":"2021-11-16","completion":"2022-11-16","firstPosted":"2020-03-05","resultsPosted":"2024-08-07","lastUpdate":"2024-08-07"},"enrollment":106,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epithelial Ovarian Cancer","Peritoneal Cancer","Fallopian Tube Cancer"],"interventions":[{"type":"DRUG","name":"Mirvetuximab Soravtansine","otherNames":["IMGN853","MIRV"]}],"arms":[{"label":"Treatment","type":"EXPERIMENTAL"}],"summary":"This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRÎ±). Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. All participants will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight administered on Day 1 of every 3-week cycle.","primaryOutcome":{"measure":"Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)","timeFrame":"Up to approximately 15 months","effectByArm":[{"arm":"Mirvetuximab Soravtansine","deltaMin":32.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":89,"countries":["United States","Australia","Belgium","Bulgaria","Czechia","Germany","Ireland","Israel","Italy","Poland","Spain"]},"refs":{"pmids":["37212825","36716407"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":106},"commonTop":["Vision blurred","Nausea","Keratopathy","Diarrhoea","Fatigue"]}}